nivolumab,ipilimumab
bms,cleveland clinic
['gu ', 'nivolumab', 'hcrn,gu16,260', '/ipi', 'hcrn,gu,16,260', 'rcc,(-irccs),(-srcc),(-urcc)', ' ipi ', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ca209,669', 'ipilimumab', 'nivo', 'cleveland ', 'bms']
tfs from ph ii study of nivo &amp; salvage nivo + ipi in clear cell arcc (hcrn gu16-260-cohort a) #gu23 nivo mono + salvage nivo/ipi results in tfs and trae-free tfs tfs was increased by, and sustained following, elective rx cessation at 96-108 wks tfs % over 36 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday